Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas
Targeted inhibition of programmed cell death-1 (PD-1) and its ligand (PD-L1) has emerged as first-line therapy for advanced non-small cell lung cancer. While patients with high PD-L1 expression have improved outcomes with anti-PD-1/PD-L1 directed therapies, use as a predictive biomarker is complicated by robust responses in some patients with low-level expression. Furthermore, reported PD-L1 levels in lung cancers vary widely and discrepancies exist with different antibodies. PD-L1 expression was thus compared by immunohistochemistry (IHC) versus RNA in situ hybridization (ISH) in 112 lung cancers by tissue microarray: 51 adenocarcinoma, 42 squamous cell carcinoma, 9 adenosquamous carcinoma, 5 carcinoid, 3 undifferentiated large-cell carcinoma, 1 large-cell neuroendocrine carcinoma, and 1 small cell carcinoma.
Source: Human Pathology - Category: Pathology Authors: Joseph D. Coppock, Ashley K. Volaric, Anne M. Mills, Alejandro A. Gru Tags: Original Contributions Source Type: research
More News: Adenocarcinoma | Brain | Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Pathology | Skin Cancer | Squamous Cell Carcinoma | Undifferentiated Carcinoma